Administrative Core
行政核心
基本信息
- 批准号:10249109
- 负责人:
- 金额:$ 36.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAcuteAdvisory CommitteesAnimal ModelAnimalsAntidotesArsenicalsBioinformaticsBiometryBullaCenters of Research ExcellenceChemicalsCollaborationsCommunicationConsultationsCore FacilityCutaneousDataEducationEnsureEpigenetic ProcessEthicsEvaluationExposure toFosteringGoalsHealth PersonnelHistone AcetylationHuman ResourcesIndividualInflammationInjuryInjury to KidneyIraqJointsKidneyLeadLeadershipLungMissionMolecularMustard AgentPathogenesisPathogenicityPathologicPopulationPre-Clinical ModelProductivityProtective AgentsQuality ControlRecommendationRegulationReportingResearchResearch PersonnelResource AllocationScientistServicesStudentsSyriaTherapeutic InterventionTimeTissuesToxic effectToxicologyTreatment EfficacyUnited States National Institutes of HealthVesicantsWarWorld War IIbasechemical threatconflict resolutiondiphenyldrug developmentdrug discoveryfirst responderlewisitemeetingsmultidisciplinaryoperationprogramsresponseservice utilizationskin lesionsmall moleculesmall molecule inhibitorsmall molecule therapeuticssoundspatiotemporalweapons
项目摘要
Abstract (Administrative Core)
The goal of the Administrative Core is to coordinate the scientific, operational, and financial operations of the
entire U54 Center of Excellence. Dr. Mohammad Athar will lead the Administrative Core and will be assisted by
the leaders of the individual projects and by the core directors. The Internal and External Advisory Committees
will offer additional advice to the Administrative Core on the scientific direction of each of the projects and the
scientific cores. The Administrative Core will provide the necessary leadership, oversight, direction, and
administrative support services necessary for the timely and ethical conduction of research related to this U54
Center of Excellence. In addition, the Administrative Core will reduce the time Project and Core leaders and
other personnel need to spend on administrative details, and allow them to concentrate on the scientific goals of
the center. The Core also will facilitate interaction and communication between components of the U54 Center
of Excellence. The Administrative Core will accomplish this with the following responsibilities: 1. To plan,
coordinate and implement the administrative activities of the Projects and Cores, and to maintain sound fiscal
management of the Projects and Cores. 2. To provide oversight to the core facilities by assuring high quality and
adequate utilization of the services provided, and to evaluate resource allocation to all projects and cores. 3. To
promote productive interactions between the Projects and Cores and to foster communication that will enhance
the exchange of ideas between Project and Core scientists. 4. To coordinate evaluation by the Internal and
External Advisory Committees. 5. To interface with officials at UAB, the National Institute of Health CounterACT
Program and other regulatory agencies to ensure that there is Institutional and NIH Compliance. To coordinate
regular meetings project and core leaders. The Administrative Core will provide regular reports to the NIH
CounterACT Program on the progress of this U54 Center of Excellence. 6. To coordinate biostatistical and
bioinformatics activities to ensure that investigators have ready access to statistical/bioinformatics consultation
and support. Additional important duties of the Administrative Core will be to provide strict fiscal oversight and
to help with conflict resolution and if any should occur to resolve them in a timely manner. Finally, to also have
oversight on quality control.
摘要(行政核心)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mohammad Athar其他文献
Mohammad Athar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mohammad Athar', 18)}}的其他基金
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10259711 - 财政年份:2020
- 资助金额:
$ 36.57万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10023318 - 财政年份:2020
- 资助金额:
$ 36.57万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10700044 - 财政年份:2020
- 资助金额:
$ 36.57万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10886403 - 财政年份:2020
- 资助金额:
$ 36.57万 - 项目类别:
Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)
核心 4:动物育种 (UAB) 和暴露核心 (MRIGLOBAL)
- 批准号:
10249112 - 财政年份:2018
- 资助金额:
$ 36.57万 - 项目类别:
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury
项目1:化学糜烂介导的皮肤损伤的新型药理抑制剂
- 批准号:
10249113 - 财政年份:2018
- 资助金额:
$ 36.57万 - 项目类别:
UAB Research Center of Excellence in Arsenicals
阿拉巴马大学砷化合物卓越研究中心
- 批准号:
9767149 - 财政年份:2018
- 资助金额:
$ 36.57万 - 项目类别:
UAB Research Center of Excellence in Arsenicals
阿拉巴马大学砷化合物卓越研究中心
- 批准号:
10249107 - 财政年份:2018
- 资助金额:
$ 36.57万 - 项目类别:
Core 3: Rexinoid Screening and Animal Core
核心 3:Rexinoid 筛选和动物核心
- 批准号:
10263928 - 财政年份:2017
- 资助金额:
$ 36.57万 - 项目类别:
Core 3: Rexinoid Screening and Animal Core
核心 3:Rexinoid 筛选和动物核心
- 批准号:
10493962 - 财政年份:2017
- 资助金额:
$ 36.57万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 36.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 36.57万 - 项目类别:
Operating Grants














{{item.name}}会员




